pipette
ESEspañol

Molecular age of Barrett's esophagus indicates onset often occurs decades before diagnosis

T. Oliveira, S. R. Reynolds, E. Scanlon, V. Child, D. T. McManus, B. Johnston, Z. Hu, S. Killcoyne, B. Nutzinger, G. Devonshire, R. C. Fitzgerald, R. C. Turkington, A. J. McKnight, H. G. Coleman, K. Curtius

PreprintReal-world use

In the authors' words

Background Timely identification of Barrett's esophagus (BE) is crucial for early esophageal adenocarcinoma (EAC) detection. Screening is recommended from age 50 in individuals with additional risk factors, but biological BE onset age remains unknown. Objective Estimate biological BE onset age and duration before clinical diagnosis (dwell time). Design We applied a BE epigenetic clock to 61 samples from 41 patients in a population-representative Northern Ireland cohort and 164 samples from 140 patients in an independent UK cohort. BE dwell times were compared between patients with concurrent dysplasia/EAC and age- and sex-matched non-dysplastic BE controls in these cross-sectional studies. In a longitudinal cohort, pre-progression biopsies from 31 future high-grade dysplasia (HGD)/EAC progressors were compared with 35 non-progressors. Results Median estimated BE onset ages in the cross-sectional cohorts were 29.5 (IQR=22.5-45.8) and 29.3 (IQR=20.4-39.0) years, respectively. These estimates were further supported by independent epidemiologic modeling of age-specific BE prevalence data from more than 70,000 BE cases. Estimated dwell times were longer in patients with concurrent dysplasia (median difference 14.3 years; p=0.0042) or EAC (12.5 years; p=0.0002) than matched non-dysplastic BE controls. Dwell time exceeding 19.8 years was associated with higher odds of HGD/EAC progression (OR=12.1, 95% CI 3.7-47.5; p=9.96 x 10-9;). Conclusion BE may arise decades before diagnosis. Although these findings do not justify lowering screening age, they suggest one-time screening from age 50 years may detect existing high-risk BE. Further modeling is warranted to evaluate implications for population-based screening, alongside prospective validation of epigenetic tissue age for progression risk stratification.

Main resultLimitation the authors admit

Appeared: Tuesday, November 17. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.13.26367463